Biosynthetic Technologies is a technology company.
Biosynthetic Technologies has raised $18.0M across 2 funding rounds.
Biosynthetic Technologies has raised $18.0M in total across 2 funding rounds.
Biosynthetic Technologies has raised $18.0M in total across 2 funding rounds.
Biosynthetic Technologies's investors include HG Ventures.
Biosynthetic Technologies is a technology company specializing in sustainable, biobased synthetic base oils and additives called estolides, derived from organic fatty acids in bio-derived oils like castor. These high-performance products serve as drop-in replacements for lubricants in industrial applications (e.g., gear oils, hydraulics, grease, metalworking fluids), personal care (e.g., emollients with enhanced stability and moisturization), and food-grade uses, targeting manufacturers seeking environmentally friendly alternatives without sacrificing performance.[1][2][4][5] Operating as a subsidiary of Calumet Specialty Products Partners since around 2013 (formerly LubriGreen Biosynthetics), the company demonstrates growth through a 25,000-gallon/year facility, Series A-II funding, and partnerships like Albemarle, while expanding into beauty via BioEstolides™ that are REACH-registered, kosher, vegan, and halal certified.[1][3][4]
Founded in 2009 (with some records noting 2013 post-rebranding from LubriGreen Biosynthetics, LLC), Biosynthetic Technologies emerged from patented USDA technology to restructure oleic acids into estolides using continuous flow processes.[1][3] The idea stemmed from addressing sustainability gaps in lubricants and chemicals, leveraging bio-derived feedstocks for superior performance over petroleum-based options. Early traction included a demonstration facility in Baton Rouge, LA (with partner Albemarle), collaborations with three of the top four U.S. motor oil producers, and a 2016 $115 million government loan guarantee commitment for a 20 million gallon/year commercial plant (targeting construction in late 2016, scaling by 2018).[3] Headquartered in Indianapolis, IN (with addresses in Irvine, CA), it evolved into a Calumet subsidiary, shifting focus from biofuels to commercial estolide production amid rising bio-materials demand.[1][2][3]
Biosynthetic Technologies rides the bio-based materials and advanced chemicals trend, capitalizing on global shifts toward sustainable alternatives amid fossil fuel depletion, stricter regulations (e.g., REACH), and corporate ESG mandates in lubricants ($150B+ market) and personal care.[1][2][4] Timing aligns with post-2010s bioeconomy growth, where drop-in biofuels/chemicals enable easy adoption without retooling—evident in their USDA-patented estolides matching or exceeding Group III+ synthetics.[3] Market forces like rising bio-feedstock availability (e.g., castor oils) and demand from automotive, manufacturing, and beauty sectors favor them, influencing the ecosystem by proving bio-oils can disrupt petroleum dominance, as seen in partnerships with majors and loan guarantees signaling policy support.[1][3][4]
Biosynthetic Technologies is poised for expansion via its Calumet backing, potential commercial plant activation (post-2018 plans), and diversification into high-margin personal care amid sustainability booms.[1][3][4] Trends like circular economies, bio-manufacturing scale-up, and green chemistry regs will propel estolides into more formulations, potentially boosting revenue from $0 (2016 est.) toward multimillion volumes.[2][3] Their influence may evolve from niche innovator to key supplier in a $ multi-billion bio-lubricants space, reinforcing that biobased synthetics like estolides deliver sustainability without compromise—echoing their core mission since inception.[1][2][4]
Biosynthetic Technologies has raised $18.0M across 2 funding rounds. Most recently, it raised $8.0M Series A in February 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2022 | $8.0M Series A | HG Ventures | |
| May 1, 2019 | $10.0M Series A | HG Ventures |